戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 um nitroprusside, an endothelium-independent nitric oxide donor.
2 ts, and compared its effects with those of a nitric oxide donor.
3 e relaxing effect of high concentration of a nitric oxide donor.
4 ine was sensitive to sodium nitroprusside, a nitric oxide donor.
5 sed to evaluate vasodilation to an exogenous nitric oxide donor.
6 CGRP in the blood following challenge with a nitric oxide donor.
7 attachment of an organic nitrate moiety as a nitric oxide donor.
8 done with 100 microM sodium nitroprusside, a nitric oxide donor.
9 n be experimentally applied to tissues using nitric oxide donors.
10 analog (8-bromo-cGMP) to mimic the effect of nitric oxide donors.
11  redox cycling compound paraquat, but not to nitric oxide donors.
12 liable experimental triggers of migraine are nitric oxide donors.
13 ther N-hydroxyurea analogues may be superior nitric oxide donors.
14 ors of nitric oxide synthase and enhanced by nitric oxide donors.
15 arallel experiments included the addition of nitric oxide donor (0.3 or 1.0 mM SNAP or PAPA-NO) to pe
16 ith IFN-gamma and TNF-alpha or the synthetic nitric oxide donor 2,2'-(hydroxynitrosohydrazino)bis-eth
17                           Interestingly, the nitric oxide donor 3-(2-hydroxy-2-nitroso-1-propylhydraz
18                                  We used the nitric oxide donor 3-morpholino-sydnonimine (SIN-1) or t
19              Nevertheless, the pharmacologic nitric oxide donors 3-morpholino-sydnonimine and S-nitro
20 erial infusion of sodium nitroprusside (SNP; nitric oxide donor), a non-metabolic vasodilatory contro
21 volving therapies, such as gene transfer and nitric oxide donor administration, which target vein gra
22                         The diazeniumdiolate nitric oxide donor agent 1-diethyl-2-hydroxy-2-nitroso-h
23  humans to enable the sustained release of a nitric oxide donor and antibody blocking immune checkpoi
24 Ca2+ signaling by exogenous application of a nitric oxide donor and found that nitric oxide induced a
25 d plasticity induced by the combination of a nitric oxide donor and hMSC therapy.
26       K-Cl cotransport (KCC) is activated by nitric oxide donors and appears to be regulated by the c
27 guanosine monophosphate levels compared with nitric oxide donors and BAY41-2272 (about 10-fold versus
28 ed with soluble guanylyl cyclase activators (nitric oxide donors and BAY41-2272) and sildenafil.
29          In a previous study, we showed that nitric oxide donors and N-acetylcysteine, either alone o
30 th those produced by the dextroisomer, other nitric oxide donors and nitric oxide itself.
31                            A wide variety of nitric oxide donors and S-nitrosating agents protect the
32 ide the development of new hydroxyurea-based nitric oxide donors and sickle cell disease therapies.
33 s are forced to generate peroxynitrite using nitric oxide donors and superoxide-generating redox cycl
34 +/-2.5 micromol/L at 12 hours, P=NS) despite nitric oxide donors and the excess ET-1 in HF-HP patient
35   Reactive free radical species generated by nitric oxide donors and the interaction of advanced glyc
36 niscal cell TGase activity was stimulated by nitric oxide donors and tumor necrosis factor-alpha, but
37                                              Nitric oxide donors (and cell-permeant cGMP analogues) a
38 c oxide), sodium nitroprusside (an exogenous nitric oxide donor), and verapamil (a calcium channel bl
39 rotected beta cells in vitro from cytokines, Nitric oxide donor, and H2O2.
40 olangiocytes with proinflammatory cytokines, nitric oxide donors, and endoplasmic reticulum stressors
41      Na,K-ATPase activity did not respond to nitric oxide donors, and the free radical-dependent step
42                             Hydroxylamine, a nitric-oxide donor, and 8-bromo-cGMP, a membrane-permean
43                                              Nitric oxide donors are often used experimentally in att
44                  Nitroglycerin, an exogenous nitric oxide donor, caused a selective vasodilatory effe
45 echnologies, including biodegradable stents, nitric oxide donor-coated stents, and a new generation o
46 sted S-nitrosylation induced in vitro by the nitric oxide donor compound S-nitroso-L-glutathione, fai
47 tance to paraquat, but not for resistance to nitric oxide donor compounds in vitro, resistance to mac
48 protein-S-nitrosylation with the addition of nitric oxide donor compounds reduced HCMV replication in
49 he 8-bromo-cGMP did not mimic the effects of nitric oxide donors (DETA-NO) on apoptosis.
50 s endogenous (coadministration of NMDA and a nitric oxide donor, diethylenetriamine NONOate) peroxyni
51 ll lines (DU145, PC-3, CL-1, and LNCaP) with nitric oxide donors (e.g. (Z)-1-[2-(2-aminoethyl)-N-(2-a
52              Topical sodium nitrite, a known nitric oxide donor, enhances blood flow in ulcers and ha
53                                Addition of a nitric oxide donor, GSNO, to WT but not CypD(-/-) MEFs p
54 ased the amount of active gelatinases, while nitric oxide donors had no noticeable effect.
55                                    All three nitric oxide donors had similar effects resulting in dos
56                                          The nitric oxide donor hydroxylamine (NH2OH) induced a trans
57                            The commonly used nitric oxide donor, hydroxylamine (NH(2)OH), can block o
58 tase (XOR) inhibition (i.e., allopurinol) or nitric oxide donors (i.e., S-nitrosoglutathione, GSNO).
59 ulline, therefore, could be a more effective nitric oxide donor in the treatment of PE.
60 dicating that its nitrate tether served as a nitric oxide donor in vivo.
61 rates the potential use of platelet-specific nitric oxide donors in the treatment of thromboembolic d
62 hese effects were similar to those seen with nitric oxide donors in this study and previous work from
63 hion to thiol redox reagents in vitro and to nitric oxide donors in vivo.
64 h muscle has led to an interest in employing nitric oxide-donors in the treatment of preterm labor.
65 ne], NOC-15 [PAPA-NO], 0.3 or 1.0 mM of each nitric oxide donor) in the presence/absence of methylene
66                        We found that various nitric oxide donors, including diethylamine NONOate (DEA
67        Phenylephrine-induced contraction and nitric oxide donor-induced relaxation were similar in al
68 nd abrogates forearm blood flow responses to nitric oxide donor infusions.
69                              DETA NONOate, a nitric oxide donor, inhibited the basal, angiotensin-II-
70                     Treatment of Hdm2 with a nitric oxide donor inhibits Hdm2-p53 binding, a critical
71 ectroencephalographic response to a cerebral nitric oxide donor (intravenous sodium nitrite) to explo
72                Vaginal administration of the nitric oxide donor isosorbide mononitrate can induce eff
73     In vitro treatment of splenocytes with a nitric oxide donor led to a decreased STAT1 IFN response
74 e threshold for spreading acidification, and nitric oxide donors lowered the threshold.
75 inflammatory and antiviral role in colds and nitric oxide donors may represent a novel therapeutic ap
76 telet free cytosolic calcium, such as direct nitric oxide donors, may be more potent overall than asp
77 aluated using 500 nM sodium nitroprusside, a nitric oxide donor (nitric oxide is important for the re
78                      HF-HP patients received nitric oxide donors (nitroglycerin/sodium nitroprusside)
79                                   The direct nitric oxide donor nitroprusside is an effective, safe t
80                                      Soluble nitric oxide donors (NO/nucleophile adducts-NONOates) ar
81                                            A nitric oxide-donor, NOC-15 ((Z)-1-[N-(3-ammoniopropyl)-N
82 thood phenocopied its loss prenatally, and a nitric oxide donor normalized kidney function in adult h
83 a cGMP analogue recapitulated the effects of nitric oxide donors on cytokine secretion.
84 , 8-bromo-cGMP, recapitulated the effects of nitric oxide donors on myocyte cytokine secretion.
85 e to cytokine stimulation, or by a synthetic nitric oxide donor, on replication of obligately intrace
86 escued by exposing cygb2 mutant embryos to a nitric oxide donor or a soluble guanylate cyclase stimul
87    In vitro, GAPC1 was inactivated by either nitric oxide donors or hydrogen peroxide, but no inhibit
88                            Microinjection of nitric oxide donors or recombinant nitric oxide synthase
89 with cytokines but not in cells treated with nitric oxide donors or with endoplasmic reticulum stress
90 macological approaches include drugs such as nitric oxide donors, phosphodiesterase inhibitors, endot
91                             We now show that nitric oxide donors positively regulate a chromosomal fl
92 dition of S-nitroso-N-acetylpenicillamine, a nitric oxide donor, prevented VEGF-induced eNOS up-regul
93                                              Nitric oxide donors produced a dose-dependent increase i
94               In addition, incubation with a nitric oxide donor promoted this interaction in vitro.
95                  Conversely, low levels of a nitric oxide donor reduced HIF-1alpha expression in norm
96                                              Nitric oxide donor-related effects were ablated by pretr
97                  Exposure of Calu-3 cells to nitric oxide donors resulted in the nitration of a numbe
98 th S-nitroso-N-acetylpenicillamine (SNAP), a nitric oxide donor, resulted in a decrease in ADH activi
99  impaired dilations to acetylcholine and the nitric oxide donor S-nitroso-N-acetyl-D,L-penicillamine
100 ion induced by either NTG or the spontaneous nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP
101 inhibitor 7-nitroindazole (7NI; 1 mM) or the nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP
102            In both HeLa and COS-7 cells, the nitric oxide donor S-nitroso-N-acetylpenicillamine incre
103 he urea transporter-A promoter, in which the nitric oxide donor S-nitroso-N-acetylpenicillamine reduc
104 cluding the calcium ionophore ionomycin, the nitric oxide donor S-nitroso-N-acetylpenicillamine, and
105 r isotonic or hypertonic conditions with the nitric oxide donor S-nitroso-N-acetylpenicillamine.
106  ADP-ribosylation reactions using a chemical nitric oxide donor S-nitrosoglutathione and enzymatic AD
107 d that systemic administration of endogenous nitric oxide donor S-nitrosoglutathione in mice blocked
108  cellular respiration by the addition of the nitric oxide donors S-nitroso-N-acetyl-DL-penicillamine
109  well) and challenged with either vehicle or nitric oxide donor (S-nitroso-N-acetyl-penicillamine [SN
110  and compare these effects with those of the nitric oxide donor, S-nitroso-N-acetylpenicillamine, an
111 ease in M-CSF expression was attenuated by a nitric oxide donor, S-nitrosoglutathione (GSNO), and by
112                    Exposure of slices to the nitric oxide donors, S-nitroso-N-acetylpenicillamine and
113                       Aorta treated with the nitric oxide donors, S-nitroso-N-acetylpenicillamine and
114                     L6 myotubes treated with nitric oxide donors, S-nitroso-N-penicillamine (SNAP, 25
115                                              Nitric oxide donors slowed the frequency of pacemaker cu
116                          The addition of the nitric oxide donors SNP or SNAP to mitogen-stimulated VS
117                                The exogenous nitric oxide donor sodium nitroprusside (1 micromol/L; n
118 ease in RBF (P < 0.05; n = 5) induced by the nitric oxide donor sodium nitroprusside (15 nmol).
119               We compared the effects of the nitric oxide donor sodium nitroprusside (SNP) on intrace
120                              Addition of the nitric oxide donor sodium nitroprusside also produced os
121 sed mice were administered a low dose of the nitric oxide donor sodium nitroprusside and mice previou
122 d acetylcholine, the endothelium-independent nitric oxide donor sodium nitroprusside and the endothel
123 n of ADP-induced platelet aggregation by the nitric oxide donor sodium nitroprusside and the phosphod
124 (P < 0.05) and sensitivity (P < 0.05) to the nitric oxide donor sodium nitroprusside were reduced in
125 duced in SH-SY5Y cells after exposure to the nitric oxide donor sodium nitroprusside, and betaine was
126  synthase was shown to be inactivated by the nitric oxide donor sodium nitroprusside.
127                             Furthermore, the nitric oxide donors sodium nitroprusside and S-nitrosogl
128 s of lipopolysaccharide were mimicked by the nitric oxide donors sodium nitroprusside and spermine NO
129  mg kg(-1)) or increasing bolus doses of the nitric oxide donor, sodium nitroprusside (SNP), were stu
130 attenuating lipid peroxidation caused by the nitric oxide donor, sodium nitroprusside (SNP).
131 methylarginine [8 mumol/min], coinfused with nitric oxide donor, sodium nitroprusside [90 to 900 ng/m
132 of NGF on ROS production was mimicked by the nitric oxide donor, sodium nitroprusside, and was blocke
133  only weakly enhanced in the presence of the nitric oxide donor, sodium nitroprusside.
134       This was confirmed with the use of the nitric oxide donor, spermine-nitric oxide complex, in an
135 l IL-6 gene expression, and application of a nitric oxide donor stimulated IL-6 gene and protein expr
136                                              Nitric oxide donors such as glyceryl trinitrate (GTN) ha
137                          Currently available nitric oxide donors such as glyceryl trinitrate or isoso
138     Nitrates such as nitroglycerin (GTN) and nitric oxide donors such as S-nitrosothiols are clinical
139 pase-3 activation and cell survival, whereas nitric oxide donors (such as 1-propamine 3-(2-hydroxy-2-
140  response to exogenous as well as endogenous nitric oxide donors suggests that the abnormality is due
141             S-nitrosoglutathione (GSNO) is a nitric oxide donor that appears to have relative platele
142                           Nitroglycerin is a nitric oxide donor that exerts potent effects on the car
143 A-MB-231 cells treated with Angeli's salt, a nitric oxide donor that has been shown to inhibit breast
144             S-nitrosoglutathione (GSNO) is a nitric oxide donor that may exert antioxidant, anti-infl
145                 In addition to their role as nitric oxide donors, there is growing evidence that thes
146   This may be prevented by the addition of a nitric oxide donor to NSAIDs.
147 tudies included examining the ability of: a) nitric oxide "donors" to alter nuclear factor kappa B (N
148 ecular changes caused by repeated stress and nitric oxide donors (two of the most common triggers of
149 eatment for sickle cell anemia and acts as a nitric oxide donor under oxidative conditions in vitro.
150                         The hepato-selective nitric oxide donor, V-PYRRO/NO, reduced hepatic resistan
151                               The effects of nitric oxide donors were mimicked by membrane-permeable
152 charide confirmed that cytokine responses to nitric oxide donors were not related to lipopolysacchari
153                                        Three nitric oxide donors were used: spermine NONOate (SP), (+
154 well as relaxation produced by exposure to a nitric oxide donor, were similar in wild-type and null m
155 nhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition pa
156                                       SNP, a nitric oxide donor, which had little toxic effect by its
157 ectiveness of S-nitrosoglutathione (GSNO), a nitric oxide donor with relative platelet specificity, i
158                                              Nitric oxide donors with longer half-lives could prove b
159  of human marrow stromal cells (hMSC) with a nitric oxide donor, (Z)-1-[N-(2-aminoethyl)-N-(2-ammonio
160           We report that administration of a nitric oxide donor, (Z)-1-[N-(2-aminoethyl)-N-(2-ammonio

 
Page Top